US2008004280A1PendingUtilityA1

Heterocyclic topoisomerase poisons

Assignee: UNIV RUTGERSPriority: Dec 31, 1997Filed: Jan 25, 2006Published: Jan 3, 2008
Est. expiryDec 31, 2017(expired)· nominal 20-yr term from priority
A61K 31/517A61K 31/4192C07D 235/20A61P 35/00A61K 31/4184C07D 403/14
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compounds of formula I: wherein R 1 to R 5 have any of the values defined in the specification, as well as pharmaceutically acceptable salts of the compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, compositions, or salts to treat cancer. In embodiments, R 4 and R 5 taken together can be a 3, 4, or 5 membered saturated or unsaturated chain comprising members selected from the group consisting of non-peroxide oxygen, sulfur, N(X), and carbon, optionally substituted by oxo; wherein each X is independently absent or is H, O, (C 1 -C 4 )alkyl, phenyl or benzyl; and wherein at least one of the chain members is an N—H group.

Claims

exact text as granted — not AI-modified
1 . A therapeutic method comprising inhibiting cancer cells by administering to a mammal in need of such therapy, an amount of a compound of formula I:  
     
       
         
         
             
             
         
       
     
     wherein: 
 R 1  and R 2  are each independently hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkoxy, nitro, hydroxyl, halo(C 1 -C 6 )alkyl, trifluoromethoxy, halo, (C 3 -C 6 )cycloalkyl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkanoyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )alkythio, (C 2 -C 6 )alkanoyloxy, aryl or heteroaryl; or R 1  and R 2  taken together are methylenedioxy; or R 1  and R 2  taken together with the atoms to which they are attached are benzo; wherein any aryl, heteroaryl, or benzo may optionally be substituted by 1, 2, or 3 substituents independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkoxy, nitro, hydroxyl, halo(C 1 -C 6 )alkyl, trifluoromethoxy, (C 3 -C 6 )cycloalkyl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkanoyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )alkylthio, (C 2 -C 6 )alkanoyloxy, and halo;  
 R 3  is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkoxy, nitro, hydroxyl, halo(C 1 -C 6 )alkyl, trifluoromethoxy, (C 3 -C 6 )cycloalkyl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkanoyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )alkylthio, (C 2 -C 6 )alkanoyloxy, or halo; and  
 R 4  and R 5  taken together are a 3, 4, or 5 membered saturated or unsaturated chain comprising members selected from the group consisting of non-peroxide oxygen, sulfur, N(X), and carbon, optionally substituted by oxo; wherein each X is independently absent or is H, O, (C 1 -C 6 )alkyl, phenyl or benzyl; and wherein at least one of said chain members is an N—H group; or a pharmaceutically acceptable salt thereof;  
 provided R 4  and R 5  taken together are not —N(H)—C(H)═N—;  
 effective to inhibit said cancer cells.  
 
   
   
       2 - 28 . (canceled)

Join the waitlist — get patent alerts

Track US2008004280A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.